[{"orgOrder":0,"company":"Ozette Technologies","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ozette Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ozette Technologies \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Ozette Technologies \/ Umoja Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by Ozette Technologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the collaboration, Umoja will leverage Ozette Endpoints™ and Ozette Discovery™ to enable both companies' multidisciplinary scientific and bioinformatic teams to collaborate and expand the benefits of CAR T-cell immunotherapy to patients in need...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Umoja Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank